Scisparc Ltd. · NASDAQ:SPRC
Scisparc — Therapix Biosciences — Investor Presentation (February 2019)
23 slides from Scisparc's investor presentation, Feb 12, 2019
Slide 1: The Cannabinoids of the Future
THE CANNABINOIDS OF THE FUTURE
Slide 2: Disclaimer
D ISCLAIMER This presentation of Therapix Biosciences Ltd. (the “Company”) contains “forward - looking statements” within the meaning of the P rivate Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimate
Slide 3: Our Vision, Our Mission
OUR VISION OUR MISSION Therapix Biosciences is a specialty clinical - stage pharmaceutical and nutraceutical company developing endocannabinoid - based solutions to address unmet needs, and bringing them to market through professional channels Connecting cannabinoids to the healthcare system to impr
Slide 4: 2018 Was an Exponential Year for the Cannabis Industry
WAS AN EXPONENTIAL YEAR FOR THE CANNABIS INDUSTRY 2018
Slide 5: Global Market in Transition: 2018 Highlights
GLOBAL MARKET IN TRANSITION 2018 HIGHLIGHTS Cannabis Is Accepted as Legitimate on Multiple Fronts President Trump signed the ‘Farm bill’, removing hemp from the list of federally controlled substances. World Health Organization (WHO) published a report stating CBD is safe and calls to exclude CBD as
Slide 6: Demonstrated Proof-of-Concept, Different Market Opportunities
DEMONSTRATED PROOF - OF - CONCEPT DIFFERENT MARKET OPPORTUNITIES Two unique platforms: Entourage and Micro - Dose in an agnostic development process suitable for botanical and synthetic APIs Our products apply to US & EU regulation with different time - to - market PHARMACEUTICAL STANDARDS IN AN EME
Slide 7: At a Glance
AT A GLANCE Connecting Cannabinoids to the Healthcare System Improving the Health and Well - being of Patients PAIN CLINICS AND LAB US - based, company - owned providing direct access to patients CLINICAL STAGE COMPANY On - going trials demonstrating potential treatments for CNS and pain indications
Slide 8: Platforms
PLATFORMS Increased Efficiency, Lower Dosage and Side Effects Therapix’s proprietary combination of any Cannabinoid and CannAmide TM creating a synergy. “The Entourage Effect” first discovered by Prof. Raphael Mechoulam in 1998 CannAmide TM Formulation of Pharma - grade Palmitoylethanolamide (PEA) w
Slide 9: Why Dose in Cannabis Is So Important
Serious diminishing effect over time and extensive use High doses may lead to unwanted psychoactive effect Compromises therapeutic benefits of cannabis severely impacts treatment Significant increase in adverse events RATIONAL Increased Efficiency, Lower Dosage and Side Effects WHY DOSE IN CANNABIS
Slide 10: Our Goal
Provide the most efficacious therapy while reducing doses and side - effects Enhance and extend cannabis and cannabinoids’ efficacy Sustain and boost ongoing treatment Help alleviate common side - effects Improve quality of life Promote compliance and benefit RATIONAL Increased Efficiency, Lower Dos
Slide 11: Edge: Comprehensive Product Offering Across Distribution Channels
EDGE Comprehensive product offering across diverse distribution channels Synthetic Cannabinoids Botanical Cannabinoids Hemp - based Botanical Cannabinoids Cannabis - based NCE THC CBD CBG CBN MOLECULE CREATE CHANNEL Partnerships Professional market Retail In combination with: CannAmide TM SOURCE Pha
Slide 12: Pharmaceuticals Pipeline
Connecting Cannabinoids to the Healthcare System to improve the Health and Well - being of Patients P HARMACUETICALS PIPELINE COMPOUND THX – 110 THERAPEUTIC AREA PRECLINICAL PHASE I PHASE IIa PHASE IIb THX – 150 THX – 160 TOURETTE’S SYNDROME OBSTRUCTIVE SLEEP APNEA PAIN ANTIBACTERIAL PAIN [
Slide 13: THX-110: Entourage Platform Combo Drug
Under the Entourage Platform, we have developed THX - 110 , a combo drug consisting of THC + CannAmide TM proven in in - vitro and in - vivo. THX - 110 is currently being developed for: THX - 110 MARKET Combining CannAmide TM with cannabinoids dramatically increases its effectiveness and duration
Slide 14: THX-110: Tourette Syndrome
THX - 110 : Increased Efficiency, Lower Dosage and Side Effects Tourette syndrome is a movement and neurobehavioral disorder characterized by motor and vocal tics, and is highly linked with co - morbidities. Our TS program is developed under 505 (b) 2 regulatory pathway, and potentially qualifies as
Slide 15: Tourette Syndrome Clinical Trial Topline Results
1. An average tic reduction of 21 % across the entire sample 2. Six of the 16 medication - refractory TS subjects experienced a response to treatment as defined by a reduction in YGTSS - TTS of greater than 25 % 3. Improvement over time with treatment 4. The medication was generally well - tolerated
Slide 16: THX-110: Obstructive Sleep Apnea
THX - 110 : Increased Efficiency, Lower Dosage and Side Effects OBSTRUCTIVE SLEEP APNEA (OSA) OSA causes breathing to repeatedly stop during sleep, and is a potentially lethal sleep disorder Breathing sleep disorders affect a substantial and growing percentage of the adult population The standar
Slide 17: OSA Phase IIa Clinical Trial
On - going phase IIa clinical trial is currently conducted in Assuta, the largest private hospital chain in Israel Intervention: 30 patients, once daily THX - 110 administration for one month period Top - line results are expected in the first half of 2019 THERAPIX PHARMACEUTICAL SOLUTION: THX
Slide 18: Pain: Worldwide Epidemic
Annual "economic burden” of prescription opiate misuse Americans suffer from chronic pain of long - term disability in the US Daily deaths by opioid - overdose US Annual cost including healthcare expenses, lost income and lost productivity Incidence of pain in the USA compared with other major condi
Slide 19: THX-160: CB2 Receptor Agonist for Pain
CB 2 R - specific agonists have been found to be involved in mediating analgesic effects in the peripheral nervous system, without significant side effects. THX - 160 : CB 2 Receptor Agonist for Acute and Chronic Pain A synthetic CB 2 R agonist NEW CHEMICAL ENTITY (NCE) THX - 160 Protected under pat
Slide 20: Three Solutions for Pain Indications
For our pain indications we have three solutions: PAIN – WORLDWIDE EPIDEMIC Short term 2019 CannAmide TM AS ADJUVANT SUPPLEMENT; Partnering with MMJ providers (B 2 B) Mid - term THX - 110 THXB - 110 THX - 160 Long - term NCE 505 (B) 2
Slide 21: EVERO Health Supplements
EVERO Health is our supplements brand CannAmide TM – For pain and inflammation: Active ingredient Palmitoylethanolamide – Endocannabinoid - like compound, a lipid - messenger and an endogenous neuromodulator with a broad spectrum of pharmacological properties and can be found naturally in the body,
Slide 22: Management and Scientific Board
DR. ASCHER SHMULEWITZ, MD PHD, CEO AND CHAIRMAN An inventor, investor and serial entrepreneur in biomedical technologies, he has founded and invested in over two dozen life sci ence companies including NeoVision Corp, Labcoat Medical Ltd. Arteria Corp, Circulation Inc. and X - Cardia Inc., and has l
Slide 23: Invest in the Cannabinoids of the Future
I NVEST IN THE CANNABINOIDS OF THE FUTURE
Therapix Biosciences — Investor Presentation (February 2019) on 6ix